Black Diamond Therapeutics, Inc.
NASDAQ: BDTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mark A. Velleca
- Employees
- 24
- Headquarters
- Cambridge, United States
- IPO year
- 2020
- Market cap
- $106.6M
- Website
- https://www.blackdiamondtherapeutics.com
Loading BDTX…
Loading profile data…Frequently asked questions about BDTX
What does Black Diamond Therapeutics, Inc. (BDTX) do?
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncoge...
Where does BDTX trade?
Black Diamond Therapeutics, Inc. (BDTX) trades on the NASDAQ Global Select.
What sector is BDTX in?
Black Diamond Therapeutics, Inc. (BDTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Black Diamond Therapeutics, Inc.?
Mark A. Velleca is the chief executive officer of Black Diamond Therapeutics, Inc. (BDTX).
Where is Black Diamond Therapeutics, Inc. headquartered?
Black Diamond Therapeutics, Inc. is headquartered in United States.
Does BDTX pay a dividend?
Black Diamond Therapeutics, Inc. (BDTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BDTX go public?
Black Diamond Therapeutics, Inc. (BDTX) completed its initial public offering in 2020.